Table 7.
Values of the Akaike information criterion (AIC), Bayesian information criterion (BIC), and pharmacokinetic objective function value (OBV) for the final stepwise model and the single-objective, hybrid, genetic algorithm (SOHGA) candidate model with the lowest fitness function value
| Compound | Final stepwise model | Final SOHGA model | AICSOHGA − AICstepwise |
|---|---|---|---|
| Citalopram, IV | BIC = 5,474.9 | BIC = 5,457.8 | −22.3 |
| AIC = 5, 391.9 | AIC = 5,369.6 | ||
| OBV = 5,359.9 | OBV = 5,335.6 | ||
| DMAG, IV | BIC = 9,942.3 | BIC = 9,920.0 | −22.3 |
| AIC = 9,871.7 | AIC = 9,849.4 | ||
| OBV = 9,843.7 | −OBV = 9,821.4 | ||
| Escitalopram [21] | BIC = 2,800.1 | BIC = 2,783.4 | −0.1 |
| AIC = 2,737.7 | AIC = 2,737.6 | ||
| OBV = 2,707.1 | OBV = 2,715.6 | ||
| Olanzapine, oral [14] | BIC = 10,413.8 | BIC = 9,937.9 | −470.5 |
| AIC = 10,365.8 | AIC = 9,895.3 | ||
| OBV = 10,347.8 | OBV = 9,879.3 | ||
| Perphenazine, oral [15] | BIC = 601.1 | BIC = 604.4 | −4.8 |
| AIC = 560.7 | AIC = 555.9 | ||
| OBV = 540.7 | OBV = 531.9 | ||
| Risperidone, oral [16] | BIC = 5,202.8 | BIC = 4,934.9 | −278.1 |
| AIC = 5,131.1 | AIC = 4,853.0 | ||
| OBV = 5,103.1 | OBV = 4,821.0 | ||
| Ziprasidone, oral [17] | BIC = 4,789.3 | BIC = 4,784.8 | −4.5 |
| AIC = 4,763.2 | AIC = 4,758.7 | ||
| OBV = 4,751.2 | OBV = 4,746.7 |